Snowball logo
logo
ONVO_logo

Organovo Holdings, Inc

ONVO • NASDAQ Не торгуется
-- $0,00 $  (0%)
Оценка
EPS
-10,08
Бета
1,134
Рост
Выручка, YoY
380%
Чистый доход, YoY
4,36%
FCF, YoY
48,86%
Другое
Размер лота
1 шт.
О компании
Тикер
ONVO
ISIN
US68620A2033
Страна
США
Сектор (GICS)
Здравоохранение
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.

Часто задаваемые вопросы

В каком секторе работает Organovo Holdings, Inc (ONVO)?

Organovo Holdings, Inc относится к сектору Здравоохранение.

Выплачивает ли Organovo Holdings, Inc (ONVO) дивиденды?

Нет, Organovo Holdings, Inc не выплачивает дивиденды.

Какой бета-коэффициент (волатильность) у Organovo Holdings, Inc (ONVO)?

У компании Organovo Holdings, Inc бета 1.134, что означает, что её волатильность примерно соответствует рыночной.